Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

Christophe Le Tourneau,Valentin Calugaru,Edith Borcoman,Victor Moreno,Emiliano Calvo,X. Liem,Sébastien Salas,Bernard Doger,Olivier Choussy,Maria Lesnik,Xavier Mirabel,Nathalie Badois,Samar Krhili,Josefin Blomkvist,Nicolas Fakhry,Stéphanie Wong Hee Kam,Caroline Hoffmann

Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

2020

Christophe Le Tourneau
Valentin Calugaru
Edith Borcoman
Victor Moreno
Emiliano Calvo
X. Liem
Sébastien Salas
Bernard Doger
Olivier Choussy
Maria Lesnik
Xavier Mirabel
Nathalie Badois
Samar Krhili
Josefin Blomkvist
Nicolas Fakhry
Stéphanie Wong Hee Kam
Caroline Hoffmann

6573Background: The standard of care non-surgical approach for locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients (pts) is concurrent chemoradiation with high dose cisplatin...

Keywords:

Cisplatin
locally advanced
Hafnium oxide
Pathology
Cancer research
Radiation therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations